Skip to main content
. 2017 Jan 7;73(4):409–416. doi: 10.1007/s00228-016-2189-8

Table 5.

Stopping rules for other/later phase I trials

• General risk assessment based on
 - exposure (e. g. high exposure in drug-drug interaction trials, supra-therapeutic exposure in thorough QT trials)
 - frequency of relevant adverse events
• Protocol to define stopping rules and decision making process for individual subjects, cohorts, and entire trial